Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs

Elevated serum gamma‐glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)‐related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB...

Full description

Saved in:
Bibliographic Details
Published in:The Kaohsiung journal of medical sciences 2024-02, Vol.40 (2), p.188-197
Main Authors: Jang, Tyng‐Yuan, Liang, Po‐Cheng, Jun, Dae Won, Jung, Jang Han, Toyoda, Hidenori, Wang, Chih‐Wen, Yuen, Man‐Fung, Cheung, Ka Shing, Yasuda, Satoshi, Kim, Sung Eun, Yoon, Eileen L., An, Jihyun, Enomoto, Masaru, Kozuka, Ritsuzo, Chuma, Makoto, Nozaki, Akito, Ishikawa, Toru, Watanabe, Tsunamasa, Atsukawa, Masanori, Arai, Taeang, Hayama, Korenobu, Ishigami, Masatoshi, Cho, Yong Kyun, Ogawa, Eiichi, Kim, Hyoung Su, Shim, Jae‐Jun, Uojima, Haruki, Jeong, Soung Won, Ahn, Sang Bong, Takaguchi, Koichi, Senoh, Tomonori, Buti, Maria, Vargas‐Accarino, Elena, Abe, Hiroshi, Takahashi, Hirokazu, Inoue, Kaori, Huang, Jee‐Fu, Chuang, Wan‐Long, Yeh, Ming‐Lun, Dai, Chia‐Yen, Huang, Chung‐Feng, Nguyen, Mindie H., Yu, Ming‐Lung
Format: Article
Language:English
Subjects:
Alanine Transaminase
Alcohol use
Body mass index
Diabetes
gamma-Glutamyltransferase
GGT
HBV
Hepatitis B
Hepatitis B, Chronic - drug therapy
Hepatitis C
Humans
Liver
Liver cancer
Liver Cirrhosis
Liver diseases
Liver Neoplasms
Medical research
Medicine, Experimental
Mortality
Nucleosides
Nucleotides
Patient outcomes
Patients
Prognosis
Regression analysis
Risk factors
Telbivudine
treatment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Elevated serum gamma‐glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)‐related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB treated with NAs were recruited from a multinational cohort. Serum GGT levels before and 6 months (Month‐6) after initiating NAs were measured to explore their association with all‐cause, liver‐related, and non‐liver‐related mortality. The annual incidence of all‐cause mortality was 0.9/100 person‐years over a follow‐up period of 17,436.3 person‐years. Compared with patients who survived, those who died had a significantly higher pretreatment (89.3 vs. 67.4 U/L, p = 0.002) and Month‐6‐GGT levels (62.1 vs. 38.4 U/L, p 
ISSN:1607-551X
2410-8650
DOI:10.1002/kjm2.12771